Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

This study has been completed.
Information provided by (Responsible Party):
Wang Weiqing, Shanghai Jiao Tong University School of Medicine Identifier:
First received: October 21, 2011
Last updated: October 24, 2011
Last verified: October 2011

Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.

Hypertension, Resistant to Conventional Therapy

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China

Resource links provided by NLM:

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Biospecimen Retention:   Samples With DNA

blood samples,including serum, plasma and whole blood.

Estimated Enrollment: 2000
Study Start Date: January 2010
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
primary aldosteronism
essential hypertension


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with resistant hypertension from different provinces of China


Inclusion Criteria:

  • patients with resistant hypertension
  • age 18-65 years

Exclusion Criteria:

  • known cause of hypertension
  • heart failure
  • renal dysfunction
  • Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
  • cirrhosis
  • pregnancy
  • undertreatment of glucocorticoid
  Contacts and Locations
Please refer to this study by its identifier: NCT01459042

China, Shanghai
Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine
Shanghai, Shanghai, China, 200025
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Principal Investigator: Weiqing Wang, MD, PhD Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine
  More Information

No publications provided

Responsible Party: Wang Weiqing, Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University School of Medicine Identifier: NCT01459042     History of Changes
Other Study ID Numbers: 19830409
Study First Received: October 21, 2011
Last Updated: October 24, 2011
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on April 22, 2014